Coageight 500 IU Injection In Pakistan

Coageight 500 IU Injection In Pakistan

Coageight 500 IU Injection contains recombinant human Coagulation Factor VIII. It is a prescription clotting-factor medicine used for the treatment and prevention of bleeding in patients with Hemophilia A, a condition associated with Factor VIII deficiency. Coageight replaces the deficient Factor VIII and helps support the body’s normal blood-clotting process.

Coageight 500 IU is supplied as a lyophilized powder for preparation before intravenous administration. The required dose is individualized according to the patient’s condition, Factor VIII levels, body weight, severity and location of bleeding, and clinical response.

Benefits

• Provides recombinant Factor VIII replacement.
• Used to help control bleeding episodes associated with Hemophilia A.
• May be prescribed for prevention of recurrent bleeding.
• Can provide Factor VIII support around certain surgical procedures when clinically indicated.
• Helps restore Factor VIII activity required for normal blood clot formation.
• 500 IU strength allows dosing according to an individualized treatment plan.

Specifications

Available product information identifies Coageight (COAGEIGHT) as recombinant Factor VIII, with a 500 IU strength and lyophilized powder formulation.

How To Use

Coageight 500 IU should be used only under the supervision of a hematologist or qualified healthcare professional.

• The dose is calculated individually according to body weight, Factor VIII level, severity and location of bleeding, and treatment response.
• The vial is prepared/reconstituted according to the manufacturer’s instructions.
• The prepared medicine is administered intravenously.
• Treatment may be given for an active bleeding episode, prophylaxis, or around an appropriate surgical procedure as determined by the treating physician.
• Do not change the dose or frequency without medical advice.
• Do not self-inject unless you have specifically been trained and instructed by your healthcare professional.

Important Safety Information

Some patients receiving Factor VIII products can develop Factor VIII inhibitors (neutralizing antibodies), which may reduce treatment effectiveness. Monitoring may be required, particularly when bleeding does not respond as expected. Hypersensitivity or allergic reactions can also occur. Seek urgent medical attention for facial or throat swelling, breathing difficulty, severe rash, or other signs of a serious allergic reaction.

Why Choose Coageight 500 IU?

• Contains recombinant Coagulation Factor VIII.
• Specifically used for Factor VIII replacement in Hemophilia A.
• Available in a 500 IU vial strength.
• Can be used for treatment or prevention of bleeding when prescribed.
• Administered under specialist medical supervision for individualized treatment.
• Suitable for patients whose physician has determined that Factor VIII replacement is appropriate.